Company intelligence / Profile preview

General Biophysics

Wayland, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

General Biophysics has completed pre-clinical studies indicating xenon gas therapy can reduce neuroinflammation and amyloid-beta plaques in animal models of Alzheimer's disease. A Phase 1 clinical trial in collaboration with Brigham Women's Hospital and Harvard Medical School is planned for late 2025[2][3].

Therapeutic areas: Neurology
Modalities: Inhalation therapyDeviceBiologic
Industry: Biotech

Partnerships

Brigham Women's HospitalHarvard Medical SchoolNational Institute on AgingNational Institute on Drug Abuse

Beyond the preview

Go deeper on General Biophysics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on General Biophysics.

Explore the full profile